Hagop Kantarjian: The latest advancements and progress in treating AML

Hagop Kantarjian shared a post on X:

“Recording now available: The latest advancements and progress in treating Acute Myeloid Leukaemia (AML).”

Additional information.
Source: Hagop Kantarjian/X

Hagop Kantarjian is the professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he also serves as the Samsung Distinguished Leukemia Chair in Cancer Medicine and Associate Vice President for Global Academic Programs.

Dr. Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia, spanning over four decades. His contributions include advancements in chronic myeloid leukemia treatment, such as tyrosine kinase inhibitors like imatinib, dasatinib, nilotinib, and bosutinib.

Moreover, he has made discoveries in acute lymphocytic leukemia, myelodysplastic syndrome, and leukemias treatment, resulting in over 20 FDA-approved drugs.